# BLR&D Research Career Scientist Award Application

> **NIH VA IK6** · JESSE BROWN VA MEDICAL CENTER · 2020 · —

## Abstract

Every day, 22 veterans complete suicide, primarily due to the ramifications of untreated depression. Due to
fear and stigma, many do not seek treatment. For those who do, about one third of the time, no drug offers
relief and even those antidepressants that do work often require 6-8 weeks before therapeutic onset.
Unfortunately, no unifying hypothesis for a molecular/cellular basis of action for antidepressant drugs (or
depressive disorders) has emerged. Over the last several years, we have suggested that, in addition to
presynaptic targets (uptake sites), a number of antidepressant drugs have a post-synaptic mechanism of
action. Toward this end, we have observed that chronic treatment (3-5 days) of cultured neural or glial cells
with a number of chemically diverse antidepressant compounds translocates the heterotrimeric G protein Gsα
out of lipid rafts and into a closer association with adenylyl cyclase. Post-mortem tissue from depressed
suicides shows just the opposite, with an increased proportion of Gsα ensconsed in lipid rafts and preliminary
data suggest that this is also observed in blood cells, where the extent of Gsα in lipid rafts correlates with both
depression and clinical response to antidepressants. Furthermore, several experimental compounds may
have antidepressant effects as well as shorter therapeutic onset, and the proposed studies will search for a
cellular “biosignature” for antidepressant action. Proposed studies will also attempt to establish a mechanistic
understanding for the translocation of Gsα from lipid rafts as a hallmark of depression and as a conduit for
antidepressant action. One aspect of this involves an investigation of the interactions between antidepressants
and lipids, particularly the omega 3 polyunsaturated fatty acids from fish oil (DHA and EPA). Another aim
involved the possibility that tubulin forms the anchor for Gsα in lipid rafts. One potential application of the
proposed studies is to develop a platform that can provide a cell-based screen for putative antidepressant
compounds as well as a screening tool to indicate personalized antidepressant choice. Another intent of these
studies is to provide a peripheral tissue biological marker for depression and an early (< 1 week) indicator of
successful antidepressant treatment that can be developed into a clinically useful, inexpensive and readily-
available biomarker for clinical use. The identification of a pathway for antidepressant action might lead to
novel antidepressant drugs, while the assignation of a quantitative value for depression may help overcome
stigma and encourage thousands of depressed veterans to seek treatment.

## Key facts

- **NIH application ID:** 9815364
- **Project number:** 5IK6BX004475-02
- **Recipient organization:** JESSE BROWN VA MEDICAL CENTER
- **Principal Investigator:** MARK M. RASENICK
- **Activity code:** IK6 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2020
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2018-10-01 → 2023-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9815364

## Citation

> US National Institutes of Health, RePORTER application 9815364, BLR&D Research Career Scientist Award Application (5IK6BX004475-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9815364. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*